Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
Martin Gauthier(Institut universitaire du cancer de Toulouse Oncopole), Loïc Ysebaert(Institut universitaire du cancer de Toulouse Oncopole), Lucie Obéric(Institut universitaire du cancer de Toulouse Oncopole), E. Martin(Institut de Cancérologie de l'Ouest), Anne Quillet‐Mary(Inserm), François Vergez(Centre National de la Recherche Scientifique), Fontanet Bijou(Institut Bergonié), Françoise Durrieu(Institut Bergonié), Michaël Pérès(Institut universitaire du cancer de Toulouse Oncopole), Thomas Filleron(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 18
Related Papers
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
|Journal of Clinical Oncology|2017|357
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network
|Journal of Clinical Oncology|2017|219
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
|Nature Communications|2020|121